Bizmut subsitrat, metronidazol ve tetrasiklin etkileşimleri

Alcoholic beverage consumption for at least three days during or after therapy. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Kontrendikasyonlar)

Antacids, Multivitamins or Dairy Products: Decreased absorption of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules; do not take concomitantly. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated (see WARNINGS: Pseudotumor Cerebri ). (Asitretin etiketi, Kontrendikasyonlar)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (Bosentan etiketi, İlaç etkileşimleri)

Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

CONTRAINDICATIONS This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the components of the product formulation. (Demeklosiklin etiketi, Kontrendikasyonlar)

Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. (Dikloksasilin etiketi, İlaç etkileşimleri)

Disulfiram usage within the last two weeks. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Kontrendikasyonlar)

Doxycycline hyclate are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (Doksisiklin etiketi, Kontrendikasyonlar)

…reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (Dronabinol etiketi, Kontrendikasyonlar)

Concomitant use of isotretinoin should be avoided because isotretinoin is also known to cause IH. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (Masitentan etiketi, İlaç etkileşimleri)

Avoid concomitant use of mebendazole and metronidazole ( 5.3 ) (Mebendazol etiketi, Uyarılar ve önlemler)

EMROSI is contraindicated in patients with a history of hypersensitivity to any of the tetracyclines [see Warnings and Precautions (5.1) ]. (Minosiklin etiketi, Kontrendikasyonlar)

Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (Nafsilin etiketi, İlaç etkileşimleri)

Drug Interactions Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided. (Oksasilin etiketi, İlaç etkileşimleri)

Drug Interactions Bacteriostatic antibacterials ( i.e. , chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided. (Penisilin G etiketi, İlaç etkileşimleri)

Antacids, Multivitamins or Dairy Products: Decreased absorption of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules; do not take concomitantly. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Avoid use in patients with known hypersensitivity to tetracyclines. (Tigesiklin etiketi, Uyarılar ve önlemler)

WARNING: POTENTIAL RISK FOR CARCINOGENICITY WARNING: POTENTIAL RISK FOR CARCINOGENICITY Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent [see Nonclinical Toxicology (13.1)]. (Tinidazol etiketi, Kutulu uyarı)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

• Concomitant administration of tetracycline reduces atovaquone concentrations; use caution when coadministering. (Atovakuon etiketi, İlaç etkileşimleri)

• Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. (Atovakuon ve proguanil etiketi, İlaç etkileşimleri)

HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (Avanafil etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Çinko, kinolon ve tetrasiklin antibiyotiklerin emilimini azaltır; antibiyotiği çinkodan en az iki saat önce veya dört ila altı saat sonra alın. (NIH Office of Dietary Supplements, Zinc)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Demir bu ilaçları bağırsakta bağlar ve emilimlerini azaltır; dozları ayrı zamanlarda alın. (NIH Office of Dietary Supplements, Iron)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (Diklofenak etiketi, İlaç etkileşimleri)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (Eleksakaftor, tezakaftor ve ivakaftor etiketi, İlaç etkileşimleri)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Inducers of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma concentrations of metronidazole. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

…antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides,… (Glimepirid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Kalsiyum bu ilaçları bağırsakta bağlar ve emilen miktarı keskin biçimde azaltabilir; dozları ayrı zamanlarda alın. (NIH Office of Dietary Supplements, Calcium)

Calcium acetate capsules may decrease the bioavailability of tetracyclines or fluoroquinolones via this mechanism. (Kalsiyum asetat etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Tetracycline and other drugs that interact with magnesium Simultaneous administration of tetracycline with quinapril hydrochloride reduced the absorption of tetracycline by approximately 28% to 37%, possibly due to the high magnesium content in quinapril tablets. (Kinapril etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride; these drugs were not tested to determine the effect of administration one hour before colestipol hydrochloride. (Kolestipol etiketi, İlaç etkileşimleri)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Kolestiramin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (Lakozamid etiketi, İlaç etkileşimleri)

Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (Lantan etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Lithium In patients stabilized on relatively high doses of lithium, short-term use of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may cause elevation of serum lithium concentrations and signs of lithium toxicity due to the interaction between metronidazole and lithium. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (Lomitapid etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Magnezyum içeren takviyeler ve antasitler bu ilaçların emilimini azaltır; dozların arasına en az iki saat koyun. (NIH Office of Dietary Supplements, Magnesium)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (Meloksikam etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Metronidazol etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (Nateglinid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

…Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

…antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides,… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Oral Contraceptives: Decreased efficacy possibly resulting in pregnancy; use a different or additional form of contraception. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (Ramelteon etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin, and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as Rocuronium Bromide Injection include certain antibiotics (e.g., aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). (Rokuronyum etiketi, İlaç etkileşimleri)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (Rosuvastatin etiketi, İlaç etkileşimleri)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (Selekoksib etiketi, İlaç etkileşimleri)

Monitor for neurologic toxicities in patients receiving metronidazole. (Siklofosfamid etiketi, İlaç etkileşimleri)

Inhibitors of CYP450 liver enzymes The simultaneous administration of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride and drugs that inhibit microsomal liver enzymes, such as cimetidine, may result in a prolonged half-life and decreased plasma clearance of metronidazole. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

…Multivitamins, or Dairy Products The absorption of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride may be reduced if administered with antacids containing aluminium, calcium, or magnesium; preparations containing iron, zinc, or sodium bicarbonate; or milk or dairy products due to the interaction between these products and tetracycline. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (Sukralfat etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

As with other antibacterial drugs, use of tetracycline hydrochloride may result in overgrowth of nonsusceptible organisms, including fungi. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (Torasemid etiketi, İlaç etkileşimleri)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

The concomitant use of other products (e.g., tetracyclines) that can cause intracranial hypertension may increase the risk. (Tretinoin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride is administered concomitantly with warfarin. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (Zafirlukast etiketi, Önlemler)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Other Antibacterials Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin. (Amoksisilin etiketi, İlaç etkileşimleri)

Bacteriostatic Antibiotics : Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins. (Ampisilin etiketi, İlaç etkileşimleri)

Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. (Ergotamin ve kafein etiketi, Uyarılar)

Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of CD including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates. (İnfliksimab etiketi, İlaç etkileşimleri)

Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (Klopidogrel etiketi, İlaç etkileşimleri)

Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (Lopinavir ve ritonavir etiketi, İlaç etkileşimleri)

Development of Potential for Microbial Overgrowth Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with an antifungal agent. (Bizmut subsitrat, metronidazol ve tetrasiklin etiketi, Uyarılar ve önlemler)

Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (Terbinafin etiketi, İlaç etkileşimleri)

The following antibiotics have been associated with various degrees of paralysis: aminoglycosides (such as neomycin, streptomycin, kanamycin, gentamicin, and dihydrostreptomycin); tetracyclines; bacitracin; polymyxin B; colistin; and sodium colistimethate. (Vekuronyum etiketi, Önlemler)

…enflurane famotidine felodipine finasteride hydrocortisone isoflurane isoniazid isradipine influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not… (Aminofilin etiketi, İlaç etkileşimleri)

There was no effect on neostigmine action on rocuronium reversal by cefuroxime, metronidazole, cefuroxime or metronidazole. (Neostigmin etiketi, İlaç etkileşimleri)

…additional doses of Cisatracurium Besylate Injection, and to determine whether adjustments need to be made to the dose with subsequent administration. † Examples: aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, sodium colistimethate Drug or Drug Class Clinical Implications * Succinylcholine The use of succinylcholine… (Sisatrakuryum etiketi, İlaç etkileşimleri)

…clinically significant interaction with theophylline.* albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without methylprednisolone sulbactam metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin… (Teofilin etiketi, İlaç etkileşimleri)